Sutro Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary

• Sutro Biopharma Inc STRO.OQ reported a quarterly adjusted loss of 59 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -81 cents. The mean expectation of eleven analysts for the quarter was for a loss of 73 cents per share. Wall Street expected results to range from -89 cents to -54 cents per share.

• Revenue fell 49.7% to $8.52 million from a year ago; analysts expected $15.25 million.

• Sutro Biopharma Inc's reported EPS for the quarter was a loss of 59 cents​.

• The company reported a quarterly loss of $48.79 million.

• Sutro Biopharma Inc shares had risen by 17.9% this quarter and lost 4.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Sutro Biopharma Inc is 11.50

This summary was machine generated from LSEG data November 14 at 04:07 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)